GlassScriptPhysician profile
Michael S Rogers
NPI 1083785976
$7,356.11
in general payments reported to CMS, 2019-2025
41 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $332 · 2021: $126 · 2022: $886 · 2023: $1,602 · 2024: $1,252 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,659.13 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $968.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $908.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $745.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.63 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $438.38 | 2019-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $419.06 | 2022-2025 | Rexulti |
| Abbvie INC. | $415.95 | 2022-2025 | Ubrelvy, Qulipta, Synthroid |
| Pfizer INC. | $379.67 | 2019-2025 | |
| Lilly USA, LLC | $291.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $213.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $201.82 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $176.87 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $116.25 | 2022-2025 | |
| Amarin Pharma, INC. | $108.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.47 | 2019-2025 | Xifaxan |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.